From 67% to 97%: That’s a big improvement

Point-of-sale edit upped % of Rx with <7 days supply

February 9, 2020

A point-of-sale edit helped decrease large opioid supplies for new users, with a 30 percent increase in prescriptions of less than seven days supply

Evidence shows that a three-day opioid prescription is enough most of the time. The Centers for Disease Control (2016) provided these guidelines, and many states have passed laws that support them. These guidelines have worked their way into doctors’ prescribing habits, but for many, it’s a slow process. This study demonstrates how benefit design can have an immediate impact on prescribing behavior. This Blue Plan implemented a point-of-sale edit to limit new opioid prescriptions to less than seven days supply. This plan’s compliance rate jumped from 67 percent to 97 percent.

Short Acting Opioid Duration Edit Substantially Reduces Large Day Supply for Commercially Insured Opioid Naïve Members Compared to a Control Group without an Edit (Fall 2019)

Related news

Perspectives

April 25, 2024

Clinical News: April 2024

Your monthly source for drug information highlights

Perspectives

April 25, 2024

Drug Approvals Monthly Update: April 2024

This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals…

Perspectives

April 25, 2024

Drug Approvals Quarterly Update: April 2024

This wrap-up provides a review of newly approved drugs, recent drug launches, new…